The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single physician to handle.

STAT

Boston

Suffolk County

Massachusetts

United States

They may be ‘miracle’ drugs, but obesity meds call for a team approach

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Boston Globe

Not everything was bright and shiny for Viking Therapeutics as 2024 came to a close. The company’s stock took a 24% tumble in December, closely tied to moves made by a formidable competitor, Merck, which is steering into the potentially lucrative obesity drug market. The Competitor: Merck’s Bold Move
In a strategic maneuver, Merck partnered with Chinese biotech Hansoh Pharma to develop an investigational obesity medication. This drug, HS-10535, …

elblog.pl

Major Pharma Battle! Merck Intensifies Obesity Drug Race

Life was improving for Carlos Campos, 72, after starting Ozempic for his type 2 diabetes. When Medicare stopped covering the drug, his blood sugar levels rose, but his diabetes educator helped him access the medication through a patient assistance program. The rise of GLP-1 drugs like Ozempic presents challenges that require a team approach to ensure access and proper treatment. However, barriers to access, affordability, and discontinuation sti…

Dataemia

Ozempic’s logistical challenges have doctors look to team approach

The Chief Scientific Advisor at Novo Nordisk, Lotte Bjerre Knudsen, was the key force who pushed hard to develop GLP-1 drugs for treating obesity and subsequently for Alzheimer’s. She was recently recognized by the 2024 Lasker Medical Research Award, and the 2024 AAAS Bhaumik Breakthrough of the Year Award. That recognition is richly deserved, since  [...]

ramaonhealthcare.com

Lotte Bjerre Knudsen: The Scientist Who Drove GLP-1 Drugs For Obesity and Alzheimer's – RamaOnHealthcare

(Axios) – The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The data, which shows double-digit growth in 23 states, offers a snapshot of the sustained growth in demand across the U.S. for the drugs hailed as game-changers in the fight against obesity. (Read More)

They may be ‘miracle’ drugs, but obesity meds call for a team approach

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics